A reason for the lower driver mutation screening rates in patients with ILD and lung cancer could be that the preexisting ILD may be associated with the development of severe drug-induced pneumonitis in NSCLC patients [104,109] treated with tyrosine kinase regimens, but this is not the case for the KRAS G12C. This evidence concerns the gene KRAS and interstitial lung disease.